<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077749</url>
  </required_header>
  <id_info>
    <org_study_id>2017-041</org_study_id>
    <nct_id>NCT04077749</nct_id>
  </id_info>
  <brief_title>Probiotic Bladder Instillation for Prevention of Catheter Associated UTIs in Chronically Catheterized Patients</brief_title>
  <official_title>A Randomized Double Blinded Study of Probiotic Bladder Instillation for Prevention of Catheter Associated UTIs in Chronically Catheterized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a randomized, placebo-controlled clinical trial to test the efficacy of&#xD;
      an oral Lactobacillus product dissolved in sterile saline and instilled into the urinary&#xD;
      bladder in an attempt to colonize the urinary bladder as well as prevent UTIs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who use a chronic indwelling urinary catheter to drain their bladder will be&#xD;
      randomized to receive intravesical instillations of a Lactobacillus solution or sterile&#xD;
      saline at the time of a scheduled monthly catheter exchange. Bacterial colonization and&#xD;
      frequency of urinary tract infections will be compared between the two groups.&#xD;
&#xD;
      The Lactobacillus solution will be derived from the combination of Lactobacillus rhamnosus&#xD;
      (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic&#xD;
      capsule sold under the brand name of Femdophilus and manufactured by CHR-Hansen of Denmark&#xD;
      (phone: +45 45747474; email: info@chr-hansen.com). The contents of the capsules will be&#xD;
      dissolved in 50 mL of normal saline at room temperature within one hour prior to&#xD;
      administration and left indwelling in the patient's urinary bladder for 30 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study never started. It was withdrawn from the IRB.&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bladder colonization with Lactobacillus</measure>
    <time_frame>6 months</time_frame>
    <description>Percent of patients with urine cultures positive for lactobacilli species after 6 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Femdophilus probiotic</intervention_name>
    <description>Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>50 mL normal saline at room temperature</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years of age&#xD;
&#xD;
          2. Chronic indwelling urethral catheter or supra-pubic tube for &gt;6 months&#xD;
&#xD;
          3. Prior symptomatic UTI while catheter in place&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunosuppressed (HIV, transplant immunosuppression, uncontrolled diabetes)&#xD;
&#xD;
          2. Active infection (may be considered after treatment of active infection)&#xD;
&#xD;
          3. Prior urosepsis requiring ICU admission&#xD;
&#xD;
          4. Significant gross hematuria resulting from catheter exchanges&#xD;
&#xD;
          5. Supravesical urinary diversion&#xD;
&#xD;
          6. Upper urinary tract anatomical abnormality&#xD;
&#xD;
          7. Obstructing urolithiasis&#xD;
&#xD;
          8. Ongoing antibiotic therapy for non-urological infection&#xD;
&#xD;
          9. Indwelling nephrostomy tube or ureteral stent&#xD;
&#xD;
         10. Radiation cystitis&#xD;
&#xD;
         11. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

